{"protocolSection": {"identificationModule": {"nctId": "NCT02623998", "orgStudyIdInfo": {"id": "REMIT-Sita"}, "organization": {"fullName": "Population Health Research Institute", "class": "OTHER"}, "briefTitle": "Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)", "officialTitle": "An Open-label, Randomized, Parallel Design Trial to Compare the Efficacy of a Sitagliptin-based Metabolic Intervention Versus Standard Diabetes Therapy in Inducing Remission of Type 2 Diabetes"}, "statusModule": {"statusVerifiedDate": "2022-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-07-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-09-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-11-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-12-04", "studyFirstSubmitQcDate": "2015-12-04", "studyFirstPostDateStruct": {"date": "2015-12-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-12-28", "resultsFirstSubmitQcDate": "2021-12-28", "resultsFirstPostDateStruct": {"date": "2022-03-14", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-03-15", "lastUpdatePostDateStruct": {"date": "2022-03-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Population Health Research Institute", "class": "OTHER"}, "collaborators": [{"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to determine whether in patients with early type 2 diabetes,a short-term intensive metabolic intervention comprising of sitagliptin, metformin, basal insulin glargine and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.", "detailedDescription": "This is a multicentre, open-label, randomized controlled trial in 100 patients with recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 12-week course of treatment with sitagliptin, metformin, insulin glargine and lifestyle therapy, or (b) standard diabetes therapy, and followed for a total of 64 weeks (1 year and 3 months). In all participants with HbA1C \\< 7.3% at the 12 week visit, glucose-lowering medications will be discontinued and participants will be encouraged to continue with lifestyle modifications and regular glucose monitoring. Participants with HbA1C \u2265 7.3% at this visit or who meet criteria for hyperglycemic relapse after stopping drugs will receive standard glycemic management as informed by the current Canadian Diabetes Association clinical practice guidelines"}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Diabetes", "Insulin", "Glargine", "Metformin", "Sitagliptin", "Diet", "Excercise", "Lifestyle"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 102, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Intervention", "type": "EXPERIMENTAL", "description": "Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy", "interventionNames": ["Drug: insulin glargine", "Drug: sitagliptin/metformin", "Behavioral: lifestyle therapy"]}, {"label": "Standard Care", "type": "NO_INTERVENTION", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "interventions": [{"type": "DRUG", "name": "insulin glargine", "description": "Dose is titrated to achieve fasting normoglycemia", "armGroupLabels": ["Intervention"], "otherNames": ["Lantus"]}, {"type": "DRUG", "name": "sitagliptin/metformin", "description": "Dose is titrated to 50/1000 mg bid or maximal tolerated dose", "armGroupLabels": ["Intervention"], "otherNames": ["Janumet"]}, {"type": "BEHAVIORAL", "name": "lifestyle therapy", "description": "Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving", "armGroupLabels": ["Intervention"], "otherNames": ["diet and exercise"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Hyperglycemia Relapse in the Experimental Group Compared to the Control Group", "description": "Hyperglycemia relapse for primary outcome was defined as any one of:\n\n1. Capillary glucose \\>10 mmol/L on \\>/=50% of readings over 1 week;\n2. HbA1C \\>/=6.5%;\n3. use of diabetes drugs;\n4. fasting plasma glucose \\>/= 7.0 mmol/L;\n5. 2-hour postprandial plasma glucose \\>/=11.1 mmol/L on an oral glucose tolerance test.", "timeFrame": "64 weeks of follow-up"}, {"measure": "Number of Participants With Severe Hypoglycemic Episodes", "timeFrame": "64 weeks of follow-up"}], "secondaryOutcomes": [{"measure": "Number of Participants Achieving Drug-free Diabetes Remission", "description": "Diabetes remission is defined as absence of hyperglycemia relapse", "timeFrame": "24 weeks after randomization"}, {"measure": "Number of Participants With Drug-free Normal Glucose Tolerance", "description": "Normal glucose tolerance is defined as a FPG\\<6.1 mmol/L and a 2-hour plasma glucose \\<7.8 mmol/L on a 75 g oral glucose tolerance test", "timeFrame": "24 weeks after randomization"}, {"measure": "Percent Change in Weight", "timeFrame": "Baseline and 12 weeks after randomization"}, {"measure": "Change in Waist Circumference", "timeFrame": "Baseline and 12 weeks after randomization"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. men and women 30-80 years of age inclusive;\n2. type 2 diabetes mellitus diagnosed by a physician within 5 years prior to patient enrollment;\n3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks prior to screening and randomization;\n4. HbA1C \u2264 9.5% on no oral hypoglycemic agents or HbA1C \u2264 8.0% on 1 oral agent or on half-maximal doses of 2 agents;\n5. body mass index \u2265 23 kg/m2;\n6. a negative pregnancy test and an agreement to use a reliable method of birth control for the duration of the trial in all females with childbearing potential;\n7. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG); ability and willingness to self-inject insulin;\n8. provision of informed consent.\n\nExclusion Criteria:\n\n1. current use of insulin;\n2. history of hypoglycemia unawareness; history of severe hypoglycemia requiring assistance within the last 5 years;\n3. renal dysfunction as evidenced by serum creatinine (Cr) \u2265 124 \u03bcmol/l;\n4. history of lactic acidosis or diabetic ketoacidosis;\n5. active liver disease or elevated alanine transferase (ALT) levels \u2265 2.5 times upper limit of normal at the time of enrollment;\n6. history of pancreatitis;\n7. cardiovascular disease including any of: a) systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 105 mmHg; b) peripheral vascular disease; c) left bundle branch block or second or third degree AV block; d) tachyarrhythmias or bradyarrhythmias with uncontrolled ventricular rate; e) stenotic valvular heart disease; f) cardiomyopathy; g) history of heart failure; h) history of aortic dissection; i) documented history of angina or coronary artery disease; j) history of stroke or transient ischemic attack;\n8. history of any disease requiring continuous systemic glucocorticoid treatment;\n9. history of any major illness with a life expectancy of \\< 3 years;\n10. history of injury or any other condition that significantly limits participant's ability to achieve moderate levels of physical activity;\n11. excessive alcohol consumption (\\>14 alcoholic drinks per week in men and \\>7 alcoholic drinks per week in women);\n12. known hypersensitivity to insulin glargine, metformin, or any DPP-4 inhibitor.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "30 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Natalia McInnes, MD", "affiliation": "McMaster University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Hertzel C Gerstein, MD", "affiliation": "Hamilton Health Sciences Corporation", "role": "STUDY_CHAIR"}], "locations": [{"facility": "University of Calgary", "city": "Calgary", "state": "Alberta", "zip": "T2T 5C7", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Health Science Centre", "city": "Winnipeg", "state": "Manitoba", "zip": "R3E 3P4", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "McMaster University", "city": "Hamilton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "St. Joseph's Hospital", "city": "London", "state": "Ontario", "zip": "N6A 4V2", "country": "Canada", "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "LMC", "city": "Markham", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.86682, "lon": -79.2663}}, {"facility": "Univeristy of Montreal", "city": "Montreal", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}]}, "referencesModule": {"references": [{"pmid": "34728531", "type": "DERIVED", "citation": "McInnes N, Hall S, Hramiak I, Sigal RJ, Goldenberg R, Gupta N, Rabasa-Lhoret R, Braga M, Woo V, Sultan F, Otto R, Smith A, Sherifali D, Liu YY, Gerstein HC; REMIT-sita Collaborative Group. Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. Diabetes Care. 2022 Jan 1;45(1):178-185. doi: 10.2337/dc21-0278."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nsitagliptin/metformin: Dose is titrated to 50/1000 mg bid or maximal tolerated dose\n\nlifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "FG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "52"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "51"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nsitagliptin/metformin: Dose is titrated to 50/1000 mg bid or maximal tolerated dose\n\nlifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "BG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "102"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.4", "spread": "8.7"}, {"groupId": "BG001", "value": "54.7", "spread": "9.3"}, {"groupId": "BG002", "value": "55.5", "spread": "9.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "38"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "64"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "89"}]}]}, {"title": "Non-Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "102"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Hyperglycemia Relapse in the Experimental Group Compared to the Control Group", "description": "Hyperglycemia relapse for primary outcome was defined as any one of:\n\n1. Capillary glucose \\>10 mmol/L on \\>/=50% of readings over 1 week;\n2. HbA1C \\>/=6.5%;\n3. use of diabetes drugs;\n4. fasting plasma glucose \\>/= 7.0 mmol/L;\n5. 2-hour postprandial plasma glucose \\>/=11.1 mmol/L on an oral glucose tolerance test.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "64 weeks of follow-up", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nsitagliptin/metformin: Dose is titrated to 50/1000 mg bid or maximal tolerated dose\n\nlifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "48"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Severe Hypoglycemic Episodes", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "64 weeks of follow-up", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nsitagliptin/metformin: Dose is titrated to 50/1000 mg bid or maximal tolerated dose\n\nlifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Drug-free Diabetes Remission", "description": "Diabetes remission is defined as absence of hyperglycemia relapse", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "24 weeks after randomization", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nsitagliptin/metformin: Dose is titrated to 50/1000 mg bid or maximal tolerated dose\n\nlifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Drug-free Normal Glucose Tolerance", "description": "Normal glucose tolerance is defined as a FPG\\<6.1 mmol/L and a 2-hour plasma glucose \\<7.8 mmol/L on a 75 g oral glucose tolerance test", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "24 weeks after randomization", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nsitagliptin/metformin: Dose is titrated to 50/1000 mg bid or maximal tolerated dose\n\nlifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change in Weight", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% change", "timeFrame": "Baseline and 12 weeks after randomization", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nsitagliptin/metformin: Dose is titrated to 50/1000 mg bid or maximal tolerated dose\n\nlifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.1", "spread": "2.5"}, {"groupId": "OG001", "value": "-1.4", "spread": "2.9"}]}]}]}, {"type": "SECONDARY", "title": "Change in Waist Circumference", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm", "timeFrame": "Baseline and 12 weeks after randomization", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nsitagliptin/metformin: Dose is titrated to 50/1000 mg bid or maximal tolerated dose\n\nlifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "3.5"}, {"groupId": "OG001", "value": "-1.8", "spread": "4.8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "64 weeks", "eventGroups": [{"id": "EG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nsitagliptin/metformin: Dose is titrated to 50/1000 mg bid or maximal tolerated dose\n\nlifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving", "deathsNumAffected": 1, "deathsNumAtRisk": 50, "seriousNumAffected": 0, "seriousNumAtRisk": 50, "otherNumAffected": 9, "otherNumAtRisk": 50}, {"id": "EG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines", "deathsNumAffected": 0, "deathsNumAtRisk": 52, "seriousNumAffected": 0, "seriousNumAtRisk": 52, "otherNumAffected": 4, "otherNumAtRisk": 52}], "otherEvents": [{"term": "Atrial flutter", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}, {"term": "Joint pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}, {"term": "Anxiety/depression", "organSystem": "Psychiatric disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 52}]}, {"term": "Vasovagal syncope", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}, {"term": "Infection", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 52}]}, {"term": "Allergic conjunctivitis", "organSystem": "Eye disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}, {"term": "Fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 52}]}, {"term": "Elective surgery", "organSystem": "Surgical and medical procedures", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 52}]}, {"term": "Superficial skin injury", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Natalia McInnes", "organization": "McMaster University", "email": "natalia.mcinnes@mcmaster.ca", "phone": "19055212100", "phoneExt": "73794"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2015-12-16", "uploadDate": "2021-12-14T10:09", "filename": "Prot_000.pdf", "size": 334607}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-11-26", "uploadDate": "2021-12-14T11:02", "filename": "SAP_001.pdf", "size": 271022}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}